Altimmune
Open
$2.61
Prev. Close
$2.61
High
$2.61
Low
$2.59
Market Snapshot
$274.19M
-3.1
-1.34
$15K
57
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 57 full-time employees. The company went IPO on 2005-10-06. The firm is focused on developing next-generation peptide-based therapeutics. The company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The firm has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The firm also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
emptyResult
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 57 full-time employees. The company went IPO on 2005-10-06. The firm is focused on developing next-generation peptide-based therapeutics. The company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The firm has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The firm also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Recently from Cashu
Novo Nordisk Launches Higher Dose Wegovy to Compete in Obesity Treatment Market
Wegovy’s Higher Dose Launch: A Strategic Response in the Obesity Market In a landscape increasingly dominated by effective obesity treatments, Novo Nordisk aims to reclaim its position with the upcomi…
Altimmune Reports Strong Q4 Earnings, Highlights Strategic Growth and Clinical Advancements
### Altimmune Reports Strong Earnings and Strategic Initiatives at Q4 Earnings Call Altimmune (NASDAQ:ALT) announces notable financial growth as it reports its fourth-quarter earnings, showcasing a su…
Altimmune Reports Strong Growth and Pipeline Developments Amid Biotechnology Market Dynamics
Altimmune’s Strategic Growth and Pipeline Advancements Take Center Stage Altimmune, a key player in the biotechnology sector, announces substantial developments in its financial performance during its…
Altimmune's Pemvidutide Receives Breakthrough Therapy Designation for Innovative Obesity Treatment
Altimmune Secures Breakthrough Therapy Designation for Pemvidutide, Paving the Way for Innovative Obesity Treatment Altimmune, Inc. (NASDAQ:ALT) reaches a significant milestone with the U.S. Food and…